New Age Alpha Advisors LLC Acquires New Stake in IQVIA Holdings Inc. (NYSE:IQV)

New Age Alpha Advisors LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 23,228 shares of the medical research company's stock, valued at approximately $4,565,000.

A number of other institutional investors and hedge funds have also made changes to their positions in IQV. Synergy Asset Management LLC bought a new position in IQVIA in the 4th quarter worth about $33,000. Lee Danner & Bass Inc. purchased a new stake in shares of IQVIA during the fourth quarter valued at $44,000. Zions Bancorporation N.A. grew its position in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after purchasing an additional 85 shares during the period. Versant Capital Management Inc increased its position in shares of IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after purchasing an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in IQVIA in the fourth quarter worth approximately $60,000. Institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

Shares of NYSE IQV traded up $1.52 during mid-day trading on Wednesday, hitting $172.76. 492,375 shares of the company's stock traded hands, compared to its average volume of 1,302,285. The company has a market capitalization of $30.46 billion, a P/E ratio of 23.03, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 1 year low of $169.37 and a 1 year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company's 50-day moving average is $192.05 and its two-hundred day moving average is $205.13.

Remove Ads

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on IQV shares. William Blair reissued an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Morgan Stanley boosted their price objective on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Royal Bank of Canada restated an "outperform" rating and set a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Citigroup reduced their price objective on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, Truist Financial restated a "buy" rating and set a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.